RESEARCH PAPER
Association between selected immune markers and low ankle-brachial index in virologically suppressed HIV-infected patients on antiretroviral therapy in Nigeria
1
Prime Health Response Initiative (PHRI)-sub-recipients of Global Fund HIV Impact Project, Ilorin, Kwara State, Nigeria
2
Department of Medical Laboratory Science, Faculty of Health Science and Technology, College of Medicine, University of Nigeria
Enugu Campus, Enugu State, Nigeria
Submission date: 2019-04-08
Final revision date: 2019-11-09
Acceptance date: 2019-11-15
Publication date: 2020-12-12
HIV & AIDS Review 2020;19(4):227-236
KEYWORDS
TOPICS
ABSTRACT
Introduction:
People living with human immunodeficiency virus (HIV) on effective antiretroviral treatment (ART) are exposed to an increased risk of cardiovascular disease, often linked to inflammation and immune activation. Ankle-brachial index (ABI) has been widely accepted as screening tool for peripheral arterial disease (PAD) and future cardiovascular events, and is inexpensive and noninvasive compared to carotid intima-media thickness measurements. This study aimed at determining the association between low ankle-brachial index and selected immune markers among virologically suppressed HIV-infected participants on ART in Kwara State, Nigeria.
Material and methods:
This analytical cross-sectional study was conducted between July 2018 and December 2018. One hundred and fifty HIV-infected participants and fifty HIV non-infected age matched controls were recruited into the study. Ankle-brachial index was measured, and peripheral arterial disease was defined as ABI of < 0.9. Cryopreserved plasma was used to evaluate interleukin (IL)-6 and sCD14. Student’s t-test and c2 test were used to compare continuous and categorical variables. Associations of CVD and immunologic markers with low ABI were assessed using logistic regression analysis.
Results:
The study group had significantly lower mean values for ABI and significantly higher mean values of IL-6 and sCD14 compared to the control group (p < 0.05). The prevalence of low ABI (14.6%) was higher in the study group compared to the control group (2%). IL-6 (OR 0.992, p = 0.087) and sCD14 (OR 0.918, p = 0.058) were not associated with low ABI in the study group.
Conclusions:
HIV-infected individuals on suppressive ART demonstrate increased levels of IL-6 and sCD14 compared to not infected controls. The impact of inflammation and immune activation on PAD in treated HIV-infection requires further investigation.
People living with human immunodeficiency virus (HIV) on effective antiretroviral treatment (ART) are exposed to an increased risk of cardiovascular disease, often linked to inflammation and immune activation. Ankle-brachial index (ABI) has been widely accepted as screening tool for peripheral arterial disease (PAD) and future cardiovascular events, and is inexpensive and noninvasive compared to carotid intima-media thickness measurements. This study aimed at determining the association between low ankle-brachial index and selected immune markers among virologically suppressed HIV-infected participants on ART in Kwara State, Nigeria.
Material and methods:
This analytical cross-sectional study was conducted between July 2018 and December 2018. One hundred and fifty HIV-infected participants and fifty HIV non-infected age matched controls were recruited into the study. Ankle-brachial index was measured, and peripheral arterial disease was defined as ABI of < 0.9. Cryopreserved plasma was used to evaluate interleukin (IL)-6 and sCD14. Student’s t-test and c2 test were used to compare continuous and categorical variables. Associations of CVD and immunologic markers with low ABI were assessed using logistic regression analysis.
Results:
The study group had significantly lower mean values for ABI and significantly higher mean values of IL-6 and sCD14 compared to the control group (p < 0.05). The prevalence of low ABI (14.6%) was higher in the study group compared to the control group (2%). IL-6 (OR 0.992, p = 0.087) and sCD14 (OR 0.918, p = 0.058) were not associated with low ABI in the study group.
Conclusions:
HIV-infected individuals on suppressive ART demonstrate increased levels of IL-6 and sCD14 compared to not infected controls. The impact of inflammation and immune activation on PAD in treated HIV-infection requires further investigation.
REFERENCES (46)
1.
Health Organization. The global burden of disease: 2004 update 2009. Available at: http://www.who.int/healthinfo/... (Accessed: 22.07.2018).
2.
Debussche X, Balcou-Debussche M, Baranderaka NA, et al. Community health education network for the preve World ntion of cardiovascular disease and diabetes in Burundi: development and first results. Glob Health Promot 2010; 17 (2 Suppl): 68-75.
3.
Hofman K, Ryce A, Prudhomme W, et al. Reporting of non-communicable disease research in low- and middle-income countries: a pilot bibliometric analysis. J Med Libr Assoc 2006; 94: 415-420.
4.
Holmes MD, Dalal S, Volmink J, et al. Non-communicable diseases in sub-Saharan Africa: the case for cohort studies. PLoS Med 2010; 7: e1000244.
5.
World Health Organization. Global status report on noncommunicable diseases 2010/2011. Available at: http://www.who.int/nmh/publica... (Accessed: 22.07.2020).
6.
El-Sadr WM, Lundgren J, Neaton JD, et al.; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
7.
Gallet B, Pulik M, Genet P, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351: 1958-1959.
8.
Friis-Møller N, Sabin CA, Weber R, et al.; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination of antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
9.
Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-media thickness measurements from the FRAM study. AIDS 2009; 23: 1841-1849.
10.
Capeau J, Caron M, Vigouroux C. Les lipodystrophies secondaires auxtraitements antirétroviraux de l’infection par le VIH [Lipodystrophy secondary to antiretroviral therapy for HIV infection]. Med Sci (Paris) 2006; 22: 531-536.
11.
Sandler NG, Sereti I. Can early therapy reduce inflammation? Curr Opin HIV/AIDS 2014; 9: 72-79.
12.
Liovat AS, Rey-Cuillé MA, Lécuroux C. Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One 2012; 7: e46143.
13.
Ingle SM, May MT, Gill MJ, et al. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis 2014; 594: 287-297.
14.
Kwiatkowska W, Knysz B, Arczynska K, et al. Peripheral arterial disease and ankle-brachial index abnormalites in young and middle-aged HIV-positive patients in Lower Silesia, Poland. PLoS One 2014; 12: 1-18.
15.
Hooi JD, Kester AD, Stoffers HE, et al. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow- up study. J Clin Epidemiol 2004; 57: 294-300.
16.
Norgren L, Hiatt WR, Dormandy JA, et al.; TASC II Working Group. Inter-society consensus for the management of peripheral artery disease (TASC II). J Vasc Surg 2007; 45 (Suppl S): S5-67.
17.
Aboyans V, Criqui MH, McClelland RL, et al. Intrinsic contribution of gender and ethnicity to normal ankle–brachial index values: The Multi-Ethnic Study of Atherosclerosis (MESA). J Vasc Surg 2007; 45: 319-327.
18.
National Population Commission, 2006. ‘Enumerators manual’, March. Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult.
19.
Treatment Panel III). The guidelines 2004. National Heart Lung and Blood Institute. Available at: http://www.nhlbi.nih.gov/guide... (Accessed: 3.08.2018).
20.
Wang H, Chow SC. Sample Size Calculation for Comparing Proportions. Wiley Encyclopedia of Clinical Trials; 2007.
21.
Félicité K, Yacouba M, Ba H, et al. Prevalence and risk factors of peripheral artery disease in black Africans with HIV infection: a cross-sectional hospital-based study. Vasc Health Risk Manag 2018; 14: 401-408.
22.
Lipsy RJ. The National Cholesterol Education Program Adult Treatment Panel III guidelines. J Manag Care Pharm 2003; 9 (1 Suppl): 2-5.
23.
Olalla J, Salas D, Del Arco A, et al. Ankle-branch index and HIV: the role of antiretrovirals. HIV Med 2009; 10: 1-5.
24.
Agu C, Usoro C, Inaku K, et al. Cross-sectional analysis of cardiovascular risk markers among obese males and females in Southern Nigeria. Scholars Journal of Applied Medical Sciences 2016; 4 (5A): 1471-1478.
25.
Uotila M, Ruoslaliti E, Engvall E. Two-site sandwich enzyme immunoassay with monoclonal antibody to human alpha-fetoprotein. J Immunol Methods 1981; 42: 11-15.
26.
Alberti K, Zimmet P, Shaw J. Metabolic syndrome: a new world‐wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
27.
McDermott MM, Liu K, Criqui MH, et al. Ankle-brachial index and subclinical cardiac and carotid disease: the multiethnic study of atherosclerosis. Am J Epidemiol 2005; 162: 33-41.
28.
Katherine S, Handan W, Matthew L. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria. Diabetes Care 2007; 30: 113-119.
29.
Poredos P, Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology 2007; 58: 309-315.
30.
Gutierrez F, Enrique B, Sergio P, et al. Relationship between ankle–brachial index and carotid intima-media thickness in HIV-infected patients. AIDS 2008; 22: 1369-1376.
31.
Periard D, Cavassini M, Taffe P, et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis 2008; 46: 761-767.
32.
Beckman J, Duncan M, Alcorn C, et al. Association of human immunodeficiency virus infection and risk of peripheral artery disease. Circulation 2018; 138: 255-265.
33.
Neuhaus J, Jacobs DR, Baker JV, et al. Markers of inflammation, coagulation, and renal function in HIV-infected adults in SMART and in two large population-based cohorts. J Infect Dis 2010; 201: 1788-1795.
34.
Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015; 16: 448-457.
35.
Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev 2014; 22: 147-151.
36.
Longenecker CT, Funderburg NT, Jiang Y, et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med 2013; 14: 385-390.
37.
Siedner MJ, Kim JH, Nakku RS, et al. Persistent immune activation and carotid atherosclerosis in HIV-infected ugandans receiving antiretroviral therapy. J Infect Dis 2016; 213: 370-378.
38.
Mangili A, Polak JF, Quach LA, et al. Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis 2011; 214: 468-473.
39.
Kuller LH, Tracey R, Belloso W, et al. Activation of inflammatory and coagulation pathways is associated with mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
43.
Lederman MM, Smeaton L, Smith KY, et al. Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of randomized, controlled trial of the AIDS Clinical Trials Group.
45.
Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011; 204: 1217-1226.
46.
Fitch KV, Srinivasa S, Abbara S, et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013; 208: 1737-1746.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
